Faron Pharmaceuticals Oy logo

FARN - Faron Pharmaceuticals Oy Share Price

332.5p -5.0  -1.5%

Last Trade - 2:51pm

Small Cap
Market Cap £170.3m
Enterprise Value £169.5m
Revenue £n/a
Position in Universe 893rd / 1826
Unlock FARN Revenue
Relative Strength (%)
1m -5.91%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -36.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.52 0.95 0.000 0.019 0.000 0.000 -100.0%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, FaronPharmaceuticals Oy revenues was not reported. Net lossincreased 28% to EUR16.9M. Higher net loss reflectsResearch and development expense - Balan increase of 35% toEUR10.8M (expense), Employee benefits increase of 38% toEUR2.9M (expense), Employee benefit increase of 43% toEUR1.7M (expense). Basic Earnings per Share excludingExtraordinary Items remained flat at -EUR0.37.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for FARN
Graphical History


FARN Revenue Unlock FARN Revenue

Net Income

FARN Net Income Unlock FARN Revenue

Normalised EPS

FARN Normalised EPS Unlock FARN Revenue

PE Ratio Range

FARN PE Ratio Range Unlock FARN Revenue

Dividend Yield Range

FARN Dividend Yield Range Unlock FARN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
FARN EPS Forecasts Unlock FARN Revenue
Profile Summary

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The Company has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. It is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. It may be used alone or in combination with other immune checkpoint molecules.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated October 24, 2006
Public Since November 17, 2015
No. of Shareholders: n/a
No. of Employees: 30
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 50,457,874
Free Float (0.0%)
Eligible for
FARN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for FARN
Upcoming Events for FARN
Frequently Asked Questions for Faron Pharmaceuticals Oy
What is the Faron Pharmaceuticals Oy share price?

As of 2:51pm, shares in Faron Pharmaceuticals Oy are trading at 332.5p, giving the company a market capitalisation of £170.3m. This share price information is delayed by 15 minutes.

How has the Faron Pharmaceuticals Oy share price performed this year?

Shares in Faron Pharmaceuticals Oy are currently trading at 332.5p and the price has moved by -6.25% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Faron Pharmaceuticals Oy price has moved by -23.94% over the past year.

What are the analyst and broker recommendations for Faron Pharmaceuticals Oy?

Of the analysts with advisory recommendations for Faron Pharmaceuticals Oy, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Faron Pharmaceuticals Oy is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Faron Pharmaceuticals Oy next release its financial results?

Faron Pharmaceuticals Oy is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Faron Pharmaceuticals Oy dividend yield?

Faron Pharmaceuticals Oy does not currently pay a dividend.

Does Faron Pharmaceuticals Oy pay a dividend?

Faron Pharmaceuticals Oy does not currently pay a dividend.

When does Faron Pharmaceuticals Oy next pay dividends?

Faron Pharmaceuticals Oy does not currently pay a dividend.

How do I buy Faron Pharmaceuticals Oy shares?

To buy shares in Faron Pharmaceuticals Oy you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Faron Pharmaceuticals Oy?

Shares in Faron Pharmaceuticals Oy are currently trading at 332.5p, giving the company a market capitalisation of £170.3m.

Where are Faron Pharmaceuticals Oy shares listed? Where are Faron Pharmaceuticals Oy shares listed?

Here are the trading details for Faron Pharmaceuticals Oy:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: FARN
What kind of share is Faron Pharmaceuticals Oy?

Based on an overall assessment of its quality, value and momentum, Faron Pharmaceuticals Oy is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Faron Pharmaceuticals Oy share price forecast 2021?

Shares in Faron Pharmaceuticals Oy are currently priced at 332.5p. At that level they are trading at 45.87% discount to the analyst consensus target price of 614.26.

Analysts covering Faron Pharmaceuticals Oy currently have a consensus Earnings Per Share (EPS) forecast of -0.435 for the next financial year.

How can I tell whether the Faron Pharmaceuticals Oy share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Faron Pharmaceuticals Oy. Over the past six months, the relative strength of its shares against the market has been 10.62%. At the current price of 332.5p, shares in Faron Pharmaceuticals Oy are trading at -4.83% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Faron Pharmaceuticals Oy PE Ratio?

We were not able to find PE ratio data for Faron Pharmaceuticals Oy.

Who are the key directors of Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy's management team is headed by:

Markku Jalkanen - CEO
Yrjo Wichmann - CFO
Ilse Piippo - VPR
Mikael Maksimow - VOP
Matti Karvonen - OTH
Frank Armstrong - NEC
Matti Manner - NVC
Juho Jalkanen - NED
Jonathan Knowles - NED
Huaizheng Peng - NED
Who are the major shareholders of Faron Pharmaceuticals Oy?

Here are the top five shareholders of Faron Pharmaceuticals Oy based on the size of their shareholding:

Syrjälä (Timo) Individual Investor
Percentage owned: 14.09% (7.11m shares)
Lind (Tom-Erik) Individual Investor
Percentage owned: 7.54% (3.81m shares)
A&B (HK) Company, Ltd. Corporation
Percentage owned: 7.54% (3.81m shares)
Jalkanen (Markku Tapani) Individual Investor
Percentage owned: 6.39% (3.23m shares)
Salmi (Marko) Individual Investor
Percentage owned: 5.32% (2.69m shares)
Similar to FARN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.